Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXL770 in Adrenomyeloneuropathy (AMN)
NCT05146284Phase 2Withdrawn
- Sponsor
- Poxel SA
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of PXL770 in adrenomyeloneuropathy (AMN), sponsored by Poxel SA. Planned start Sep 2023; status: withdrawn.
02
Drugs
PXL770
03
Conditions
adrenomyeloneuropathy (AMN)
Beyond the preview
Go deeper on NCT05146284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05146284.